Jennifer Hall
Nurse Practitioner · Dunlap, IANPI 1225188220
Payments from drug & device makers
Across 74 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$343
- AstraZeneca$137
- Novo Nordisk$119
- Lilly USA, LLC$114
- Viatris Specialty LLC$91
- GSK$57
- plus $341 from 13 others
What the payments were for
- Food & beverage$1,17998%
- Education$232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 21 | $343 |
| AstraZeneca | 8 | $137 |
| Novo Nordisk | 7 | $119 |
| Lilly USA, LLC | 7 | $114 |
| Viatris Specialty LLC | 5 | $91 |
| GSK | 4 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Bayer | 3 | $49 |
| Amgen | 3 | $42 |
| Pfizer | 2 | $32 |
| Novartis | 2 | $30 |
| Merck | 2 | $29 |
| Exact Sciences | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Vertex | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$1,202 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 42 | $54,673 |
| EliquisApixaban | 39 | $47,267 |
| MounjaroTirzepatide | 41 | $47,251 |
| TrulicityDulaglutide | 31 | $29,306 |
| OzempicSemaglutide | 29 | $26,739 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $22,733 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $20,329 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $20,241 |
| JanuviaSitagliptin Phosphate | 29 | $18,398 |
| XareltoRivaroxaban | 13 | $14,718 |
| MyrbetriqMirabegron | 28 | $13,232 |
| KerendiaFinerenone | 14 | $12,939 |
| JardianceEmpagliflozin | 19 | $12,452 |
| Memantine Hcl ErMemantine Hcl | 52 | $8,594 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $119 | $81,41271 claims |
| Lilly USA, LLCMounjaro, Trulicity | $114 | $76,55672 claims |
| PfizerEliquis | $32 | $47,26739 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $57 | $26,91133 claims |
| AstraZenecaBreztri Aerosphere | $137 | $20,24131 claims |
| MerckJanuvia | $29 | $18,39829 claims |
| BayerKerendia | $49 | $12,93914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Dunlap
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
- Abbey ModlinDes Moines$12K
- Jonathon HenningsWaterloo$11K
- Michaela JohnsonWaterloo$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.